AstraZeneca will sell its facility in West Chester, Ohio, to biomanufacturer National Resilience, according to a Nov. 29 press release.
Financial details of the deal, including its value, were not made public, Resilience said in an email to Manufacturing Dive.
As part of the multi-year supply agreement, Resilience will continue to manufacture specific AstraZeneca medications.
The transaction of the 580,000-square-foot West Chester facility is expected to close in early 2023. Resilience will retain the factory’s employees and leadership and has no plans to make changes to the facility at this time, the company said in an email. Resilience will also acquire the site’s operations and physical assets.
National Resilience launched in November 2020, with a focus on expanding access to vaccines and medications with new manufacturing technologies while protecting against supply chain disruption.
The Ohio site is equipped with end-to-end drug product manufacturing capabilities, including aseptic filling, inspection, packaging, labeling, and cold-chain operations for vials, cartridges, pre-filled syringes, and autoinjectors, as well as a virtual reality training center.
“The West Chester site will play an important role in the delivery of our mission to broaden access to complex medicines, protect biopharmaceutical supply chains, and strengthen domestic preparedness,” Rahul Singhvi, co-founder and CEO of Resilience, said in a statement.
Andrew Wirths, senior vice president of AstraZeneca’s Americas Supply Region, said in the release the deal is part of the company’s plan to bolster its supply network.
“As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimising our manufacturing footprint to meet the evolving needs of our pipeline and portfolio,” said Wirths. “The transfer of our West Chester site to Resilience will enable the continued supply of AstraZeneca medicines to patients.”
